

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Donepezil,Mefloquine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THN201 significantly increased EEG power in the gamma band related to cognitive activity. Similar profile with respect to other pharmacological, pharmacokinetic and tolerance endpoints was observed.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 15, 2020
Lead Product(s) : Donepezil,Mefloquine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Mefloquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
Details : Mefloquine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Malaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 25, 2011
Lead Product(s) : Mefloquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
